Clinical development of insulin-like growth factor receptor—1 (IGF-1R) inhibitors: At the crossroad?

Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells

(2010) B. C. Browne et al.   ANNALS OF ONCOLOGY

Biological Rationale and Current Clinical Experience With Anti-Insulin-Like Growth Factor 1 Receptor Monoclonal Antibodies in Treating Sarcoma

(2010) David Olmos et al.   CANCER JOURNAL

Molecular Analysis of Non-Small Cell Lung Cancer Identifies Subsets with Different Sensitivity to Insulin-like Growth Factor I Receptor Inhibition

(2010) A. Gualberto et al.   CLINICAL CANCER RESEARCH

Development of an Integrated Genomic Classifier for a Novel Agent in Colorectal Cancer: Approach to Individualized Therapy in Early Development

(2010) T. M. Pitts et al.   CLINICAL CANCER RESEARCH

Insulin-like Growth Factor Receptor 1 (IGF1R) Gene Copy Number Is Associated With Survival in Operable Non–Small-Cell Lung Cancer: A Comparison Between IGF1R Fluorescent In Situ Hybridization, Protein Expression, and mRNA Expression

(2010) Rafal Dziadziuszko et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy

(2010) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies

(2010)   LANCET ONCOLOGY

Targeting Insulin-Like Growth Factor Signaling: Rational Combination Strategies

(2010) D. Olmos et al.   MOLECULAR CANCER THERAPEUTICS

Combination of Two Insulin-Like Growth Factor-I Receptor Inhibitory Antibodies Targeting Distinct Epitopes Leads to an Enhanced Antitumor Response

(2010) J. Dong et al.   MOLECULAR CANCER THERAPEUTICS

High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients

(2009) V. Ludovini et al.   ANNALS OF ONCOLOGY

Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma

(2009) Paul Haluska et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Activation of Meiosis-Specific Genes Is Associated with Depolyploidization of Human Tumor Cells following Radiation-Induced Mitotic Catastrophe

(2009) F. Ianzini et al.   CANCER RESEARCH

Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung Cancer

(2009) Daniel D. Karp et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

(2009) David Olmos et al.   LANCET ONCOLOGY

Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer

(2009) J. Zha et al.   MOLECULAR CANCER THERAPEUTICS

Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions

(2009) A Gualberto et al.   ONCOGENE

High Expression Levels of Total IGF-1R and Sensitivity of NSCLC Cells In Vitro to an Anti-IGF-1R Antibody (R1507)

(2009) Yixuan Gong et al.   PLoS One

Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients

(2008) C. Braconi et al.   ANNALS OF ONCOLOGY

Feedback Mechanisms Promote Cooperativity for Small Molecule Inhibitors of Epidermal and Insulin-Like Growth Factor Receptors

(2008) E. Buck et al.   CANCER RESEARCH

Heterogeneity of Receptor Function in Colon Carcinoma Cells Determined by Cross-talk between Type I Insulin-like Growth Factor Receptor and Epidermal Growth Factor Receptor

(2008) Y. P. Hu et al.   CANCER RESEARCH

Co-Targeting Insulin-Like Growth Factor I Receptor and HER2: Dramatic Effects of HER2 Inhibitors on Nonoverexpressing Breast Cancer

(2008) A. K. Chakraborty et al.   CANCER RESEARCH

The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) and Rationale for Combining with EGFR/HER2 Inhibitors

(2008) F. Huang et al.   CANCER RESEARCH

The Type 1 Insulin-Like Growth Factor Receptor Pathway

(2008) M. M. Chitnis et al.   CLINICAL CANCER RESEARCH

Preclinical Targeting of the Type I Insulin-Like Growth Factor Receptor in Adrenocortical Carcinoma

(2008) Ferdous M. Barlaskar et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Insulin-Like Growth Factor-I Activates Gene Transcription Programs Strongly Associated With Poor Breast Cancer Prognosis

(2008) Chad J. Creighton et al.   JOURNAL OF CLINICAL ONCOLOGY

Cross-Talk Between the ErbB/HER Family and the Type I Insulin-Like Growth Factor Receptor Signaling Pathway in Breast Cancer

(2008) Quanri Jin et al.   JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA

The insulin-like growth factor system and sarcomas

(2008) Bart Rikhof et al.   JOURNAL OF PATHOLOGY

HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924

(2008) P. Haluska et al.   MOLECULAR CANCER THERAPEUTICS

Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors

(2008) C. Tarn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA